Industry & Policy News

[ALX Oncology Holdings, Inc.] ALX Oncology Holdings Inc. announced it has entered into a clinical trial collaboration and supply agreement with Sanofi to evaluate the combination of evorpacept, a CD47 blocker, and SARCLISA, Sanofi’s monoclonal antibody that targets a specific epitope on the CD38 receptor on multiple myeloma cells, for the treatment of patients with relapsed or refractory multiple myeloma.

[Weill Cornell Medicine] Dr. Matthew Greenblatt has been awarded the Pershing Square Foundation’s Maximizing Innovation in Neuroscience Discovery (MIND) Prize to support his work studying how bone cells may influence Alzheimer’s disease progression.

[Incyte] Incyte announced that the European Commission has granted a marketing authorization for Opzelura® (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.

[Medigene AG] Medigene AG reported final Phase I dose escalation results from first-in-human Study of HLA-A*02:01-restricted PRAME-specific T cell receptor engineered T cell (TCR-T) therapy for high-risk myeloid and lymphoid neoplasms.

[Cornell University] Joeva Barrow, assistant professor of molecular nutrition in the Division of Nutritional Sciences in the College of Human Ecology, won a 2022 Hartwell Individual Biomedical Research Award, which funds scientists pursuing early stage, cutting-edge biomedical research to advance children’s health.

[Case Western Reserve University] Researchers from Case Western Reserve University (CWRU) and University Hospitals Cleveland Medical Center (UH) have secured $6.2 million from two grants awarded in the same month from the National Institutes of Health (NIH) to predict cardiovascular disease through new artificial intelligence approaches.